Additionally, a deeper understanding of the underlying molecular drivers of breast cancer pathogenesis has led to the development of a range of targeted treatments, for example, to hormone receptors, human epidermal receptor 2 (HER2) receptors, or programmed death receptor ligand 1, allowing an era of personalized medicine to be realized (2). This evidence concerns the gene ERBB2 and breast cancer.